Alligator Bioscience concludes successful project for AstraZeneca

Alligator Bioscience AB has successfully run a project for AstraZeneca. With the aid of its patented technology, this IDEON-based company has been able to considerably improve the properties of a protein for AstraZeneca – indeed, after a shorter development time than estimated.

These positive results have been achieved thanks to Alligator’s FIND™ technology, which with the aid of genetic engineering facilitates improvement of the properties of individual proteins for drugs and diagnostic applications. This technology offers a more reliable way of refining proteins than conventional methods, whilst facilitating faster and more cost-effective

development work.

"The fact that AstraZeneca chose Alligator’s technology was an important milestone in our work of establishing ourselves in the field of drug development. The clear results we have now achieved in a relatively short time underline the advantages of our technology over conventional methods of development and refinement of proteins," comments Dr Nils Siegbahn, CEO of Alligator Bioscience AB.

For further general information please visit www.alligatorbioscience.com or www.astrazeneca.com

Both companies are members of Medicon Valley Academy